Generalized Anxiety Disorder (GAD) Market Size and Share, Trends, Epidemiology and Market Research Forecast Report 2030 | Generalized Anxiety Disorder (GAD) Market Report

DelveInsight launched a new report on “Generalized Anxiety Disorder (GAD) Market 2030. It will deliver:

1. An in-depth understanding of the disease,
2. Historical and forecasted epidemiology,
3. Market trends in the 7MM

Some of the key insights from the Generalized Anxiety Disorder (GAD) market report:

• Overview of Generalized Anxiety Disorder (GAD) pathophysiology, various diagnostic approaches & treatment algorithm
• Pipeline analysis across different stages of development (Phase III & Phase II), different emerging trends and comparative analysis of pipeline products, key cross -competition, launch date
• Detailed Market size by therapies
• Historical as well as forecasted epidemiology

View our full report: www.delveinsight.com/sample-request/generalized-anxiety-disorder-gad-market

Generalized Anxiety Disorder (GAD) Overview

Generalized Anxiety Disorder (GAD) is characterized by persistent and excessive worry about a number of different things. People with GAD may anticipate disaster and may be overly concerned about money, health, family, work, or other issues. Individuals with GAD find it difficult to control their worry. They may worry more than seems warranted about actual events or may expect the worst even when there is no apparent reason for concern.

GAD is diagnosed when a person finds it difficult to control worry on more days than not for at least six months and has three or more symptoms. This differentiates GAD from worry that may be specific to a set stressor or for a more limited period of time.

 Generalized Anxiety Disorder (GAD) Signs and Symptoms:

• Feeling nervous, irritable, or on edge
• Having a sense of impending danger, panic or doom
• Having an increased heart rate
• Breathing rapidly (hyperventilation), sweating, and/or trembling
• Feeling weak or tired
• Difficulty concentrating
• Having trouble sleeping
• Experiencing gastrointestinal (GI) problems

Generalized Anxiety Disorder (GAD) Epidemiology Insights

• As per DelveInsight estimates, the 12-month prevalent population of Generalized Anxiety Disorder in 7MM was found to be 16,606,987 in 2017. Among all the countries, the estimates show the highest population of GAD in the US in 2017.
• Among the EU5 countries, France has the highest prevalent cases with 1,304,965 cases in 2017, followed by the UK. On the other hand, Spain had the lowest prevalent population.
• The Age-specific cases were divided into 18-24 yrs., 25-34 yrs., 35-49 yrs., 50-64 yrs. and 65 and above years. The highest cases are observed in the age group of 18-24 yrs.

Request for sample pages of our report @https://www.delveinsight.com/sample-request/generalized-anxiety-disorder-gad-market

The report offers Generalized Anxiety Disorder (GAD) Epidemiology in the 7MM for the study period 2017 to 2030 segmented by:

• Age-specific Prevalent Population of Generalized Anxiety Disorder (GAD)
• Number of Generalized Anxiety Disorder (GAD) Patients on Prescription Medications by Different Class
• Severity-specific Prevalent Population of Generalized Anxiety Disorder (GAD)
• Total Prevalent Population of Generalized Anxiety Disorder (GAD)
• Number of Generalized Anxiety Disorder (GAD) Patients on Prescription Medications by different Class

Many companies that have shifted their focus toward this therapeutic area are:

• Bionomics,
• Fabre-Kramer Pharmaceuticals
• Sage Therapeutics,
• VistaGen Therapeutics
• Forest Laboratories/ Allergan
• And others.

Scope of the report:

• Geography Covered: United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan
• Study Period: 3-year historical and 11-year forecasted analysis (2017-2030)
• Epidemiology Segmentation: Gender Specific, Age Specific, Severity Specific, Total diagnosed etc.
• Companies Covered: Bionomics, Fabre-Kramer PharmaceuticalsSage Therapeutics,VistaGen TherapeuticsForest Laboratories/ Allergan and others.
• Comparative Analysis: Comparative and conjoint analysis of emerging therapies.
• Case Studies
• KOL’s Views

Click here and get access to free sample pages of the report.

Reason to Purchase our report:

• Bespoke primary and secondary research
• 24*7 post-sale customer support
• Option for customizing and personalizing research reports as per needs

DelveInsight’s Generalized Anxiety Disorder (GAD) Market Insights, Epidemiology and Market Forecast–2030‘ report proffers an in-depth understanding of Generalized Anxiety Disorder (GAD), its etiology, and manifestations, a detailed analysis of the disease historical as well as forecasted epidemiology trends, its prevalence, incidence and patient pool.

The report covers the comprehensive layout of the available marketed or approved therapies for Generalized Anxiety Disorder (GAD) and the upcoming therapies in the pipeline in the Generalized Anxiety Disorder (GAD) market with unmet needs, market drivers and barriers that may impact the growth of the market size in the next decade in the 7MM.

Moreover, the Generalized Anxiety Disorder (GAD) Market Insights report lays in front the therapy that has the potential to occupy the significant chunk of the Generalized Anxiety Disorder (GAD) market, competitors’ analysis, key collaborations, licensing opportunities, R&D scenario and significant non-profit organizations working for Generalized Anxiety Disorder (GAD) patients’ relief.

Table of Contents

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.

Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us:

Shruti Thakur

[email protected]

+1(919)321-6187

Media relations:

Kritika Rehani

[email protected]

www.delveinsight.com

clarkcountyblog.com/